Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts.
Jason VincentSonya E L CraigMette L JohansenJyosthna NarlaStefanie AvrilAnalisa DiFeoSusann M Brady-KalnayPublished in: Diagnostics (Basel, Switzerland) (2021)
In this sample set, all PDXs and high-grade ovarian cancer samples had increased labeling by SBK4-TR compared with the normal controls. Our results indicate that proteolyzed PTPmu and its novel peptide detection agent, SBK4, allow for the visualization of tumor-specific changes in cell adhesion molecules by tissue-based staining, providing a rationale for further development as an imaging agent in aggressive solid tumors, including gynecological cancers.